Benefits of Rosuvastatin in Cardiovascular Protection Remain Unclear After HOPE-3

Article View

The Review of Diabetic Studies,2016,13,4,212-214.
Published:February 2017
Type:Letter to Editor
Author(s) affiliations:

Yu-Hung Chang1, Der-Wei Hwu1,2, Wei-Pin Kao3, and Yau-Jiunn Lee1

1Lee’s Endocrinology Clinic, 130 Min-Tzu Rd, Pingtung 90000, TAIWAN.

2Graduate Institute of Clinical Medicine, Kaohsiung Medical University, 100 Shih-Chuan 1st Road, Kaohsiung 80708, TAIWAN.

3MoonCome Cardiovascular Clinic, 318 Heti Rd, Sanmin Dist., Kaohsiung City 80794, TAIWAN.


The use of commercialized statins in the prevention of cardiovascular diseases (CVD) has commonly been accepted based on the informative results of the Cholesterol Treatment Trialists (CTT) reports [1] As an additional effort in the prevention of CVD, professional societies have issued practical recommendations for healthcare providers on the effective use of statins in lowering low-density-lipoprotein cholesterol (LDL-C)[2]. Among these statins, atorvastatin and rosuvastatin are regarded as the most effective as they can reduce more than 30% of LDL-C, even at low doses (i.e. atorvastatin 10 mg; rosuvastatin 5 mg) [2]. The results of the recent HOPE-3 study [3], in which 10 mg rosuvastatin was found to reduce the development of CVD by 24% in intermediate-risk persons, may reinforce the role of rosuvastatin in CVD prevention. However, there are some concerns regarding the use of rosuvastatin.